Tango Therapeutics (TNGX) Income towards Parent Company: 2020-2025
Historic Income towards Parent Company for Tango Therapeutics (TNGX) over the last 6 years, with Sep 2025 value amounting to $15.9 million.
- Tango Therapeutics' Income towards Parent Company rose 154.46% to $15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$100.5 million, marking a year-over-year increase of 18.57%. This contributed to the annual value of -$130.3 million for FY2024, which is 28.07% down from last year.
- As of Q3 2025, Tango Therapeutics' Income towards Parent Company stood at $15.9 million, which was up 140.88% from -$38.9 million recorded in Q2 2025.
- Over the past 5 years, Tango Therapeutics' Income towards Parent Company peaked at $15.9 million during Q3 2025, and registered a low of -$39.9 million during Q1 2025.
- Moreover, its 3-year median value for Income towards Parent Company was -$29.2 million (2024), whereas its average is -$26.8 million.
- Its Income towards Parent Company has fluctuated over the past 5 years, first slumped by 951,806.78% in 2021, then surged by 154.46% in 2025.
- Over the past 5 years, Tango Therapeutics' Income towards Parent Company (Quarterly) stood at -$22.1 million in 2021, then plummeted by 31.98% to -$29.1 million in 2022, then decreased by 5.65% to -$30.8 million in 2023, then declined by 22.37% to -$37.6 million in 2024, then soared by 154.46% to $15.9 million in 2025.
- Its Income towards Parent Company stands at $15.9 million for Q3 2025, versus -$38.9 million for Q2 2025 and -$39.9 million for Q1 2025.